Literature DB >> 11675354

Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation.

D T Jones1, K Ganeshaguru, A E Virchis, N I Folarin, M W Lowdell, A B Mehta, H G Prentice, A V Hoffbrand, R G Wickremasinghe.   

Abstract

Ligation of the cell-surface Fas molecule by its ligand (Fas-L) or agonistic anti-Fas monoclonal antibodies results in the cleavage and activation of the cysteine protease procaspase 8 followed by the activation of procaspase 3 and by apoptosis. In some leukemia cell lines, cytotoxic drugs induce expression of Fas-L, which may contribute to cell killing through the ligation of Fas. The involvement of Fas, Fas-L, and caspase 8 was studied in the killing of B-cell chronic lymphocytic leukemia (B-CLL) cells by chlorambucil, fludarabine, or gamma radiation. Spontaneous apoptosis was observed at 24-hour incubation, with additional apoptosis induced by each of the cytotoxic treatments. Although Fas mRNA expression was elevated after exposure to chlorambucil, fludarabine, or gamma radiation, Fas protein levels only increased after irradiation. Therefore, Fas expression may be regulated by multiple mechanisms that allow the translation of Fas mRNA only in response to restricted cytotoxic stimuli. None of the cytotoxic stimuli studied here induced Fas-L expression. An agonistic anti-Fas monoclonal antibody (CH-11) did not significantly augment apoptosis induction by any of the death stimuli. A Fas-blocking antibody (ZB4) did not inhibit spontaneous, chlorambucil-, fludarabine-, or radiation-induced apoptosis. However, procaspase 8 processing was induced by all cytotoxic stimuli. These data suggest that the Fas/Fas-L signaling system does not play a major role in the induction of apoptosis in B-CLL cells treated with cytotoxic drugs or radiation. However, Fas-independent activation of caspase 8 may play a crucial role in the regulation of apoptosis in these cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675354     DOI: 10.1182/blood.v98.9.2800

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Effect of radiation treatment on newly established human breast cancer cell lines MACL-1 and MGSO-3.

Authors:  Caryne Margotto Bertollo; Cristiane Rodrigues Correa; Dawidson Assis Gomes; Elaine Maria Souza-Fagundes; Alfredo Miranda Goes
Journal:  Tumour Biol       Date:  2010-04-27

2.  Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.

Authors:  Bella Patel; Aditi Dey; Ehsan Ghorani; Shaji Kumar; Yogeshkumar Malam; Lena Rai; Andrew J Steele; Jennifer Thomson; R Gitendra Wickremasinghe; Yu Zhang; Anna Z Castleton; Adele K Fielding
Journal:  Mol Ther       Date:  2011-03-22       Impact factor: 11.454

3.  Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

Authors:  Rajesh Kumar Gandhirajan; Peter Anton Staib; Katharina Minke; Iris Gehrke; Günther Plickert; Axel Schlösser; Esther Katharina Schmitt; Michael Hallek; Karl-Anton Kreuzer
Journal:  Neoplasia       Date:  2010-04       Impact factor: 5.715

Review 4.  Intractable and highly active relapsing multiple sclerosis - role of alemtuzumab.

Authors:  Divyanshu Dubey; Christopher A Cano; Olaf Stuve
Journal:  Neuropsychiatr Dis Treat       Date:  2015-09-18       Impact factor: 2.570

5.  Rhizoctonia bataticola lectin (RBL) induces caspase-8-mediated apoptosis in human T-cell leukemia cell lines but not in normal CD3 and CD34 positive cells.

Authors:  Radha Pujari; Sachin M Eligar; Natesh Kumar; Srikanth Barkeer; Vishwanath Reddy; Bale M Swamy; Shashikala R Inamdar; Padma Shastry
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

6.  CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.

Authors:  Zuzana Berkova; Shu Wang; Xue Ao; Jillian F Wise; Frank K Braun; Abdol H Rezaeian; Lalit Sehgal; David M Goldenberg; Felipe Samaniego
Journal:  J Exp Clin Cancer Res       Date:  2014-10-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.